Lithium is a naturally occurring silvery-white alkali metal that is so soft that it can be cut with a knife and floats in water. It is also a chemical element and is in position number three (atomic number) in the periodic table of elements. Lithium compounds have a wide variety of uses most commonly in the production of lithium batteries but are also important in the manufacture of glass and ceramics, in metallurgy, air purification and in optics.
Lithium salts were first used as a medicine to treat gout in the early 19th century based on the observation that they were effective in dissolving uric acid crystals that in gout accumulate in the kidney and bladder as well as in swollen painful joints that are characteristic of the disease. Their use was popularized by a prominent English physician, Alfred Baring Garrod, who in 1848 demonstrated that gout was associated with increased levels of uric acid in the blood. He also advocated that they be used for the treatment of 'irregular gout', a rather poorly defined condition that included mood disturbances and "gouty mania" and went so far as to suggest the lithium be used prophylactically for the treatment of recurrent mood disorders. Another physician, Alexander Haig, believed that high levels of uric acid in the blood contributed to the symptoms in migraine, depression and mania and wrote widely on the concept of "uric acid diathesis". A leading Philadelphia neurologist, Silas Weir Mitchell, recorded using the medication for the treatment of seizures and as a sedative in some patients. However, it was William Hammond a professor of neurology in New York and former Surgeon General, who in 1871 was the first to document the effectiveness of 'bromide of lithium" for the treatment of acute mania. The most extensive documentation of the effectiveness of lithium salts for the prophylactic treatment of periodic depression in the 19th century was in a 1886 monograph by Danish neurologist Carl Lange who described the successful treatment of 700-800 patients.
Despite the apparent success of Lange using lithium in the treatment of mental disorders its use for these conditions declined in the early 20th century as the promotion of lithium as a general nostrum for a wide spectrum of medical conditions beginning with gout but extending to back pain, rheumatism, headache and even as an anti-malarial agent, began to grow. The popularity of lithium as a general medical panacea led to the production and sale of lithiated spring water and even beer. However, the use of lithium had declined by the 1940s when the significant side effects of its medicinal use were becoming obvious. One of its few remaining roles for its use in the the medical armamentarium was as a salt substitute (as lithium chloride) in patients with heart disease. A report of the death of several of these patients because of the toxic effects of lithium led to the FDA banning the use of the substance in the United States in 1949, coincidentally the same year that a paper on the beneficial effects of lithium in the treatment "psychotic excitement" (mania) that presaged its current role in treatment of mental disorders was published by Dr. John Cade, a psychiatrist in Australia.
Cade who believed that toxins excreted in the urine of patients with mania might be related to the disorder performed experiments in which he injected urea into guinea pigs many of whom died because of seizures. When he added another toxin to the urea injection, uric acid in the form of its lithium salt, all of the guinea pigs survived. The injection of the lithium urate alone into the animals was associated with a short period of lethargy but no other ill effects. Cade concluded that lithium may have both anti-convulsant and anti-manic properties. In the 1949 paper he went on to describe ten patients with manic-depressive disorder treated with lithium all of whom showed significant improvement that could be sustained with long term administration of the drug. Several years later in 1954, a Danish psychiatrist Morgens Schou and his colleagues reported the beneficial effect of lithium in 34 patients in which lithium was administered with placebo control in at least some of the patients. Over the next few decades studies in many different countries confirmed the efficacy of lithium in the treatment of acute mania and bipolar disease. The development of a method to measure lithium levels in the blood in 1958 made it possible to monitor lithium dosing and toxicity. In 1970, the FDA lifted the ban on the medicinal use of lithium and approved its use for treating bipolar disease. Currently, lithium is the 197th most commonly prescribed drug in the USA with more then 2 million prescriptions annually.
The history of lithium illustrates the roles of serendipity, persistence and chance in medicine. Lithium was first used as a medication because it dissolved uric acid crystals in the joints and kidney/bladder of patients with gout, however, it does not lower the elevated uric acid levels in the blood which cause gout and is not an effective treatment for the disease. Uric acid and other toxic substances were thought to be the cause of depression, mania and other disturbances of mood - the uric acid diathesis - hence the rationale for using lithium to treat these disorders. After nearly a century of the inconsistent use of lithium in small numbers of subjects, it was finally established that it is effective in treating bipolar disease. Following decades of controversy, recent data suggest that subjects with bipolar disease do in fact have blood uric acid levels that are higher than those without the disease. However, although lithium is an effective treatment of bipolar disease, it does not lower blood uric acid levels and its exact mechanism of action in the disease is not known.